Evolus

Evolus

Evolus launched in 2012 under the name Miramar Labs but reorganized and rebranded after Alphaeon Corporation acquired a major stake, ultimately spinning the entity out as a public company in 2018. David Moatazedi, who previously led U.S. aesthetics at Allergan, became CEO the same year and has since built Evolus around a single molecule: prabotulinumtoxinA, a 900 kDa botulinum toxin type A complex sourced from South Korea's Daewoong Pharmaceutical. That sourcing relationship provides the cost structure that underpins Evolus's entire competitive posture. The company's sole commercial product is Jeuveau, an injectable neurotoxin approved by the FDA in February 2019 for the temporary improvement of moderate-to-severe glabellar lines. Evolus markets Jeuveau directly to consumers and clinicians as a lower-priced, lifestyle-branded alternative to Botox, running the product through an Evolus-branded loyalty program rather than Allergan's category-leading Brilliant Distinctions platform. The firm competes in the $4 billion-plus U.S. neurotoxin aesthetic market against Allergan (Botox), Revance (Daxxify), Merz (Xeomin), and Galderma (Dysport). In 2021, Evolus settled a multi-year trade-secrets lawsuit with Allergan and Medytox by paying a $35 million upfront settlement and agreeing to a mid-single-digit royalty on U.S. Jeuveau sales through the patent cliff — a settlement the company funded via a debt raise to preserve commercial momentum (per SEC filing, 2021). Evolus is publicly listed on Nasdaq under the ticker EOLS. As of mid-2024, the company was generating approximately $250 million in annual net revenue, driven almost entirely by Jeuveau in the U.S. market. The company runs a lean operation out of Newport Beach, California; it does not operate its own manufacturing facilities and instead relies on Daewoong for supply. In July 2024, Evolus entered the European filler market through the acquisition of a dermal-filler portfolio from Symatese, adding a physical-product line alongside the neurotoxin franchise (per Evolus press release, July 2024). The company also operates an expanding digital loyalty program, Evolus Rewards, as a direct patient-retention mechanism tied to the cash-pay aesthetic business model. Evolus's structural differentiator is its pricing architecture rather than scientific novelty. Where Allergan built Botox as a physician-trust brand, Evolus built Jeuveau as a consumer-price play — the only publicly traded pure-play neurotoxin company whose entire narrative turns on the patent-expiry window for the category leader. The company's future depends on whether mid-teens volume growth in the aesthetics market can outrun price compression as competing toxins proliferate.